Matthew Kaplan

Stock Analyst at Ladenburg Thalmann

(2.80)
# 1,717
Out of 5,116 analysts
26
Total ratings
62.5%
Success rate
19%
Average return

Stocks Rated by Matthew Kaplan

United Therapeutics
Oct 31, 2024
Maintains: Buy
Price Target: $319$344
Current: $469.49
Upside: -26.73%
UroGen Pharma
Jun 14, 2024
Maintains: Buy
Price Target: $48$54
Current: $19.61
Upside: +172.82%
TG Therapeutics
May 2, 2024
Maintains: Buy
Price Target: $39$40
Current: $29.43
Upside: +35.92%
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $15$30
Current: $42.39
Upside: -29.23%
Ardelyx
Aug 3, 2023
Maintains: Buy
Price Target: $7.5$8.5
Current: $7.69
Upside: +10.53%
Avadel Pharmaceuticals
May 2, 2023
Maintains: Buy
Price Target: $15$16
Current: $21.57
Upside: -25.82%
Kiora Pharmaceuticals
Feb 8, 2023
Reiterates: Buy
Price Target: $1,071
Current: $2.40
Upside: +44,525.00%
Beyond Air
Jun 29, 2022
Maintains: Buy
Price Target: $340$460
Current: $1.19
Upside: +38,555.46%
Lipocine
Dec 10, 2020
Upgrades: Buy
Price Target: $51
Current: $9.00
Upside: +466.67%
Cogent Biosciences
Oct 14, 2020
Initiates: Buy
Price Target: $16
Current: $35.91
Upside: -55.44%
Initiates: Buy
Price Target: $45
Current: $7.08
Upside: +535.59%